Pivotal studies, such as RISE/RIDE (NCT00473382/NCT00473330) and VIVID/VISTA (NCT01331681, NCT01363440) have established the critical role of anti-VEGF intravitreal injections in the treatment of diabetic macular edema (DME) by exhibiting better visual outcomes than focal macular laser photocoagulation. This evidence concerns the gene VEGFA and diabetic macular edema.